CAS: 4033-40-3; (S)-2-Acetamido-4-Amino-4-Oxobutanoic Acid

该化合物是一种氨酸衍生物,其特点是附于氮原子中的乙酰集团存在,这种改变增强了其在极地溶剂中的溶性,并可能影响其生物活动;N-乙酰lasparagine的分子式反映了碳,氢,氮和氧原子的存在,氨酸是典型的,在生物化学研究和应用中经常使用,特别是在蛋白合成和新陈代谢研究中.N-乙酰lasparagine可以作为各种代谢途径中的子体或中间体,其腐蚀作用可能会影响蛋白的稳定性和功能.此外,它在细胞信号和调节方面可以发挥作用.该化合物一般在标准的实验室条件下保持稳定,但应当与所有化学物质一样谨慎处理,以避免潜在危害.其特性,如熔点和溶解性,可以因环境条件和其他化合物的存在而有所不同.

结构式图片

相似化合物

163277-78-9 60079-22-3 26117-27-1

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

CAS号70-47-3 L-天冬酰胺

合成工艺路线路线简述

    L-天冬酰胺,4-硝基苯基乙酸酯置于sodium Hydroxide体系中,用 1,4-二氧六环,水 作为反应溶剂,化学反应生成 N-乙酰-L-天门冬酰胺
    参考文献:在1,4-二恶烷水溶液中与酯反应的α-氨基酸反应性
    标题:在1,4-二恶烷水溶液中与酯反应的α-氨基酸反应性
    摘要:研究了一系列α-氨基酸与4-硝基苯基乙酸酯,4-硝基苯基苯甲酸酯和2,4,6-三硝基苯基苯甲酸酯在1,4-二恶烷水溶液中的反应动力学.涉及乙酸4-硝基苯酯和2,4,6-三硝基苯甲酸苯酯的反应动力学符合布朗斯台德依赖性,并揭示了速率常数对数与α-氨基酸阴离子前沿轨道的能量差之间的线性关系.
    DOI:10.1134/s1070363218010127

    海关参考信息

    专利信息


    专利号:JP-H06507378-A
    优先权日:1990-11-21
    标题:Synthesis of equimolar mixtures of oligomers, especially mixtures of oligopeptides

    专利号:US-11472838-B2
    优先权日:2018-04-17
    标 题:Inhibitors of blood coagulation factor XIII
    发明人:HILS MARTIN; PASTERNACK RALF; BÜCHOLD CHRISTIAN
    权利人:ZEDIRA GMBH
    摘要:The invention relates to a compound of general formula (I) as novel inhibitor of blood coagulation factor XIII, methods for synthesis thereof and to use thereof for the prophylaxis or treatment of diseases associated with blood coagulation factor XIII.

    专利号:US-9217012-B2
    优先权日:2009-04-08
    标题 :Inhibitors of protein tyrosine phosphatases
    发明人:ZHANG ZHONG-YIN; ZHANG SHENG
    权利人:ZHANG ZHONG-YIN; ZHANG SHENG; UNIV INDIANA RES & TECH CORP
    摘要:Disclosed herein are compounds that selectively inhibit members of the PTP family of enzymes. Synthesized compounds demonstrated selective inhibition of TC-PTP. Also provided are methods of using the compounds and formulations containing the compounds. Also described is a fluorescence-tagged combinatorial library synthesis and screening method. And methods of using these compounds to effect enzyme activity both in cells and in vitro as well as method of using these compounds to treat diseases in human and animals.

    专利号:EP-2078025-A2
    优先权日:2006-09-22
    标 题:Process for the synthesis of clopidogrel and new forms of pharmaceutically acceptable salts thereof

    专利号:RU-2126381-C1
    优先权日:1992-08-26
    标 题 :Methods of synthesis of bicyclic amidinohydrazones (variants) and bicyclic hydroxyamidines

    专利号:WO-2008034912-A2
    优先权日:2006-09-22
    标 题:Process for the synthesis of clopidogrel and new forms of pharmaceutically acceptable salts thereof
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献

    [参考文献]: David N Guilfoyle, Et Al. The Apparent Dependence Of The Diffusion Coefficient Of N-Acetylaspartate Upon Magnetic Field Strength: Evidence Of An Interaction With Nmr Methodology. Nmr Biomed. 2003 Dec;16(8):468-74.
    [参考文献]: E I Chazov, Et Al. [参考文献]: Dokl Akad Nauk. 1996 Dec;351(4):567-70.
    [参考文献]: K Sugahara, Et Al. Liquid Chromatographic-Mass Spectrometric Analysis Of N-Acetylamino Acids In Human Urine. J Chromatogr B Biomed Appl. 1994 Jul 1;657(1):15-21.
    [参考文献]: M A Namboodiri, Et Al. Murine Aspartoacylase: Cloning, Expression And Comparison With The Human Enzyme. Brain Res Mol Brain Res. 2000 May 5;77(2):285-9.
    [参考文献]: Stella Blasel, Et Al. Stripe-Like Increase Of Rcbv Beyond The Visible Border Of Glioblastomas: Site Of Tumor Infiltration Growing After Neurosurgery. J Neurooncol. 2011 Jul;103(3):575-84.

    合成参考文献


    摘要:HANSCH,C ET AL. (1995)
    参考文献:10.1016/j.neulet.2004.03.043|10.1016/s0304-3940(04)00355-6
    摘要:Kulak W, Sobaniec W, Kubas B, Walecki J. Proton magnetic resonance spectroscopy in children with spastic diplegia. Neurosci Lett. 2004 Jun 03;363(1):62–4. doi: 10.1016/j.neulet.2004.03.043.
    参考文献:10.1007/s11064-019-02829-x
    摘要:Chen L, Chao Y, Cheng P, Li N, Zheng H, Yang Y. UPLC-QTOF/MS-Based Metabolomics Reveals the Protective Mechanism of Hydrogen on Mice with Ischemic Stroke. Neurochem Res. 2019 Aug;44(8):1950–63. doi: 10.1007/s11064-019-02829-x.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知